HTD News and Press, John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest From 03/13/24

2024-03-13 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-23 17:16:32 ET Summary Calamos Investments has launched the Calamos CEF Income & Arbitrage ETF offering. The CCEF ETF uses a fund-of-funds approach, investing in closed-end funds trading at attractive discounts and providing higher distributions. The new CCEF ETF i...

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...

2024-02-15 03:24:24 ET Summary The John Hancock Tax-Advantaged Dividend Income Fund offers a high level of current income with an 8.70% yield, higher than the S&P 500 Index and Alerian MLP Index. The fund focuses on common equities, particularly utility stocks, which provide s...

2024-02-13 09:48:22 ET More on John Hancock Tax-Advantaged Dividend Income Fund PDT And HTD: Exploiting Discounts In Closed-End Funds John Hancock ETFs announced renewal of share repurchase program Dividend scorecard for John Hancock Tax-Advantaged Dividend Income Fu...

2024-02-09 09:13:02 ET Summary For those who invest for dividends, the goal is to look for securities that can guarantee sustainable dividends and distributions over time. Choices about how to deploy the income generated by those instruments are personal and depend on each investo...

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5...

MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...

MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormo...